Forte Biosciences Inc. (FBRX)

Forte Biosciences' stock has experienced several notable events in the past six months. The stock price increased by over 120% on a six-month basis and 265.21% over the last 12 months. In April 2026, the company announced a proposed public offering and priced a $150 million public offering, leading to a stock price increase. In March 2026, the company announced its 2025 results and provided an update, which was followed by a stock price decrease. Forte also reported inducement grants under Nasdaq Listing Rules on March 4 and March 17, 2026, with stock price changes of -4.66% and -6.01% respectively. In February 2026, Forte Biosciences announced plans to present at upcoming investor meetings, resulting in a stock price change. In January 2026, the company's market cap fell and a new major risk related to share price stability was identified, noting the stock's high volatility.

Forte Biosciences, Inc. does not exhibit typical demand seasonality for its products or services. The demand for its product candidate, FB102, would be driven by the prevalence of the diseases it aims to treat and the progress and success of its clinical trials and eventual market approval, rather than seasonal fluctuations.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company in the Biotechnology industry, focusing on pharmaceutical preparation manufacturing and drug discovery. The company is developing FB102, an anti-CD122 monoclonal antibody therapeutic candidate, for autoimmune and autoimmune-related indications like celiac disease, vitiligo, and alopecia areata. Forte Biosciences is evaluating FB102 in clinical trials for these conditions. Previously, the company was developing FB-401 for inflammatory skin diseases, but development was stopped in August 2021.

Forte Biosciences, Inc. is headquartered in Dallas, Texas, United States. The company has subsidiaries that include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd, indicating an international corporate structure.

Forte Biosciences has experienced a challenging but rehabilitative period in its brand reputation over the past year. After scrapping FB-401, the company shifted its focus to FB102. The company has since rebounded from near-liquidation, raising $150 million in April 2026 and advancing FB102 on multiple fronts, including positive Phase 1b efficacy data in celiac disease. However, a major risk was identified regarding the company's share price stability, noting its high volatility. Additionally, a large shareholder, Funicular Funds, publicly criticized the company's board of directors.

Forte Biosciences, Inc. is predominantly owned by institutional shareholders, who hold 82.98% of the company. Insiders own 44.42%, and retail investors hold 0.00% of the stock. Major institutional owners include Federated Hermes Inc., Fred Alger Management LLC, Janus Henderson Group Plc, Orbimed Advisors Llc, Affinity Asset Advisors, LLC, Tybourne Capital Management (hk) Ltd, Vanguard Group Inc, and Point72 Asset Management, L.P. The largest individual shareholder is Steven Michael Oliveira.